AEON Biopharma, Inc. (AEON)
ASE · Healthcare · Biotechnology
$0.71
+2.88%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$18.8M
Shares Outstanding
26.3M
Exchange
ASE
Currency
USD
About AEON Biopharma, Inc.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -4.3M | -2.5M | -5.5M | -5.9M |
| Net Income | -6.6M | -4.5M | -37.1M | -11.8M |
| Diluted EPS | $-0.60 | $-0.39 | $nan | $-0.29 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | |
| Operating Income | -48.4M | -27.8M | -16.3M | |
| Net Income | -52.6M | 42.0M | -39.2M | |
| Diluted EPS | $-172.03 | $nan | $72.93 | $-3.95 |